BUSINESS

Quake Causes Eye Drug Maker to Stop Shipments Except Refrigerated Meds

January 10, 2024

Nitto Medic, an eye drug specialist headquartered in Toyama, said on January 9 that it is suspending the shipments of all products excluding refrigerated medicines due to the impact of a massive New Year’s Day earthquake in central Japan.

Although the company has a certain level of inventories, the quake crippled its automated warehouse, making it impossible to take out the stored products. Urgent repair work is now underway, and the timeline for re-supplies will be announced once the company has a clear prospect, it said in a letter posted in its healthcare professional website.

Subject to the shipment suspension are 69 products, predominantly eye drops.

Meanwhile, generic and OTC drug manufacturer Kyorin Rimedio also said the same day that it is suspending the shipments of four products (two APIs). A contractor logistics firm confirmed the damage to these products after the temblor, it explained. The damage to the building is not extensive, and at this point, the company sees no problem to the supply of other products, it said.

Related Article

BUSINESS

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

By Tatsuya Otsuka

Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…

By Philip Carrigan

We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…